Cancer testing backlog 2023 – biotech rescue?

Cancer testing backlog 2023 – biotech rescue?

Continue reading →

Will Monkeypox trigger a similar C19 scenario?

Will Monkeypox trigger a similar C19 scenario?

Continue reading →

A new era in cancer diagnosis

A new era in cancer diagnosis

Continue reading →

Vaccine variety is the key to ending pandemics

Vaccine variety is the key to ending pandemics

Continue reading →

Drug approval in the healthcare markets EU vs. US

Drug approval in the healthcare markets EU vs. US

Continue reading →

Will smaller biotech companies challenge or replace the current cohort of Big Pharma?

Will smaller biotech companies challenge or replace the current cohort of Big Pharma?

The Financial Times released an article on 14 August 2020 highlighting the significant increase in healthcare IPOs of companies that are working towards a Covid-19 vaccine. According to Martin Steinbach, Head of EY’s IPO and listing services EMEIA, “2020’s initial...

Continue reading →

AI beats human diagnostics

AI beats human diagnostics

A team of researchers from Google Health, working closely with researchers from North America, published a report recently in JAMA Oncology that showcased how their Artificial Intelligence (AI) diagnostic systems outperformed general pathologists in determining the degree of advancement...

Continue reading →

Horseshoe crab blood is key to making a Covid-19 vaccine – but the ecosystem may suffer

Horseshoe crab blood is key to making a Covid-19 vaccine – but the ecosystem may suffer

In 2016 a synthetic alternative (rFC) to horseshoe crab blood, used in bacterial infection detection for injectable procedures, was licensed. And yet horseshoe crabs are both threatened with extinction and in line for preservation due to Covid-19 and its...

Continue reading →

How will the rise of biosimilars impact biologics

How will the rise of biosimilars impact biologics

● Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. Biosimilars were mainly brought in to thwart the monopoly power of biologics in the pharmaceutical industry. ● Biosimilars are expected to increase at...

Continue reading →

Competition lowers drug prices, FDA says

Competition lowers drug prices, FDA says

According to a report by the US Food and Drug Administration (FDA), increased generic drug entry will lead to price reductions in the market (see our table below) as well as huge savings opportunities for patients, or at least...

Continue reading →